Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| PLAYSTUDIOS | 2021 | Post Ipo Debt | $75.0M | Las Vegas |
| Illumio | 2021 | Series F | $225.0M | Sunnyvale |
| DOOR | 2021 | Post Ipo Equity | $190.0M | New York |
| NiKang Therapeutics | 2021 | Series C | $200.0M | Wilmington |
| Vividion Therapeutics | 2021 | Series C | $135.0M | San Diego |
| Cofense | 2021 | Debt Financing | Undisclosed | Leesburg |
| Design Therapeutics | 2021 | Series B | $125.0M | Solana Beach |
| EverlyWell | 2021 | Secondary Market | $75.0M | Austin |
| KeyMe Locksmiths | 2021 | Series F | Undisclosed | Hebron |
| Coupang | 2021 | Post Ipo Equity | Undisclosed | Seoul |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 301 | PLAYSTUDIOS | Post Ipo Debt | $75.0M | Las Vegas, United States |
| 302 | Illumio | Series F | $225.0M | Sunnyvale, United States |
| 303 | DOOR | Post Ipo Equity | $190.0M | New York, United States |
| 304 | NiKang Therapeutics | Series C | $200.0M | Wilmington, United States |
| 305 | Vividion Therapeutics | Series C | $135.0M | San Diego, United States |
| 306 | Cofense | Debt Financing | Undisclosed | Leesburg, United States |
| 307 | Design Therapeutics | Series B | $125.0M | Solana Beach, United States |
| 308 | EverlyWell | Secondary Market | $75.0M | Austin, United States |
| 309 | KeyMe Locksmiths | Series F | Undisclosed | Hebron, United States |
| 310 | Coupang | Post Ipo Equity | Undisclosed | Seoul, South Korea |
PLAYSTUDIOS is the developer and operator of award-winning free-to-play casual games for mobile and social platforms.
Illumio is a cybersecurity platform specializing in breach containment and Zero Trust segmentation across hybrid environments.
DOOR provides integrated hardware and software solutions.
NiKang Therapeutics is a biotech company focused on discovering and developing small molecule oncology medicines.
Vividion is a developer of a novel drug discovery platform designed to offer transformative treatments to patients with serious illnesses.
Cofense provides phishing threat management and remediation solutions to the world's leading brands and organizations.
Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders.
EverlyWell is a digital health company that offers consumer testing, virtual care, at-home collection tests, and digital results.
A leading provider of local locksmith services across 50 states and America’s #1 provider of key duplication kiosks.
Coupang is an e-commerce platform that offers a wide variety of products, including apparel, electronics, and home goods.
Symphony Communication Services Holdings is a messaging platform that offers a range of communication products, and real-time data services.
Sigilon Therapeutics is a biotech company that specializes in creating immune-privileged products for treating acute and chronic diseases.
Decibel Therapeutics is a hearing company focused on discovering and developing new medicines to protect, repair, and restore hearing.
LianBio aims to develop and accelerate availability of paradigm-shifting medicines to patients in China.
Postmates is an on-demand food delivery platform that gives customers access to restaurants and retailers.
BlackRock has invested in 315 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
BlackRock's top investment sectors include Biotechnology, Health Care, Mobile Apps, Software, Apps. The firm invests across 44 different industry categories.
Among tracked funding rounds, LianBio received $310.0M in a Series A round. BlackRock's total known invested capital is $77.0B.
BlackRock's average investment size is $287.2M across its portfolio of 315 companies.
Recent BlackRock portfolio additions include PLAYSTUDIOS, Illumio, DOOR, NiKang Therapeutics, Vividion Therapeutics. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors